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CHAPTER I
Introduction 
Impairment of intra operative visibility due to bleeding is problem during 
otorhinolaryngologic surgeries especially in endoscopic surgeries like FESS. 
Bleeding in the surgical field can lead to incomplete surgical procedure 
which increases further bleeding and increased risk of complications due to 
non visualization of important structures. During these surgeries a slightest 
bleeding at the surgical area would look larger due to magnifying effect of 
the microscope which could upset surgical comfort. Controlled hypotension 
is one of the anesthetic techniques used to reduce bleeding during 
endoscopic surgeries. There are varieties of methods and medications used 
to obtained deliberate hypotension. 
 
The ideal hypotensive agent should be non toxic, maintain cerebro vascular 
auto regulation, no change in cardiac function, have short term effect and be 
easily titrated1, 2. Alpha 2 agonists like clonidine augment hypotensive action 
and therefore reduce bleeding3,4,5. Dexmedetomidine another highly 
selective Alpha 2 agonist acts by central mechanism and reduces bleeding.  
 
  I have chosen this study to evaluate the effect of dexmedetomidine on the 
intraoperative isoflurane requirement to maintain mean arterial pressure of  
60-70mmHg, quality of surgical field and awakening time in patients 
undergoing FESS.  
CHAPTER II 
Hypotensive anesthesia 
Hypotensive anesthesia is a technique, used intra operatively to help to 
minimize the surgical blood loss, thereby decreasing the need for blood 
transfusion. By providing a clear surgical field they also decrease the 
duration of surgery. Most important need in microscopic surgeries is 
provision of a clear vision. 
 
DEFINITION:   
Defined as either of the following 6 
• Reduction of the systolic blood pressure to 80-90mmHg 
• Reduction of mean arterial pressure (MAP) to 50-65 mmHg 
• 30% reduction of baseline MAP 
 
INDICATIONS: 
• Oromaxillofacial surgery 
• Endoscopic sinus microsurgery 
• Middle ear microsurgery 
• Spinal surgery 
• Neuro surgery 
• Major orthopaedic surgery 
• Prostatectomy 
• Liver transplant surgery 
CONTRAINDICATIONS: 
 
• Congenital heart disease 
 
• Severe anemia 
 
• Coronary artery disease 
 
• Congestive heart failure 
 
• Poorly controlled hypertension 
 
• Increased intracranial pressure 
 
• Significant cerebro-vascular disease 
 
• Extremes of age 
 
• Hypovolemia 
 
METHODS USED FOR INDUCING HYPOTENSION 
 
• Physiologic technique 
 
• Pharmacologic technique 
PHYSIOLOGIC TECHNIQUES 
 
• Body positioning 
 
• Hemodynamic effects of mechanical ventilation 
 
• Changes in  heart rate & circulatory volume 
 
PHARMACOLOGIC TECNIQUES: 
 
Pharmacological agents can generally be divided into two 
 
 
1. Inhalational   agents 
 
Commonly used inhalation agents are halothane and isoflurane. The 
concentration of a volatile anesthetic agent produces a dose dependent 
decrease in mean arterial pressure. They have negative inotropic and 
vasodilatory effects.  
2. Peripheral vasodilators 
 
The three most commonly used vasodilators are: sodium Nitroprusside 
(SNP), Nitroglycerin (NTG) and Trimethaphan.  
SNP acts as a vascular smooth muscle relaxant and has a rapid onset but 
brief duration of action. Its primary influence is on arteriolar and venous 
vessels, but without significant myocardial effects.  
NTG reduces blood pressure by relaxing venous smooth muscle and, like 
SNP, has rapid onset of action but short duration. NTG is less toxic than 
SNP; however, it is less potent than SNP in its capacity to reduce blood 
pressure. 
Trimethaphan produces hypotension through ganglionic blockade and 
direct vasodilator properties. It is also short acting and provides tight control 
of blood pressure. 
 
Beta blocker  by decreasing   myocardial contractility used for this purpose. 
The main disadvantage is bronchospasm. 
 
Alpha2 agonists like clonidine and dexmedetomidine are also used for this 
purpose. 
 
Remifentanil an opioid receptor agonist is also used for controlled 
hypotension. They have rapid onset and offset. No need for additional 
hypotensive agents.  
 
Spinal and epidural anesthesia can also be used to produce controlled 
hypotension. 
 
 
 
 
 
 
CHAPTER III 
Functional Endoscopic Sinus Surgery 
Functional endoscopic sinus surgery is the primary approach used today for 
the surgical treatment of chronic sinusitis. 
The aim of Functional Endoscopic Sinus Surgery (FESS) is to restore the 
drainage and aeration of the Para nasal sinuses, while maintaining the 
natural mucociliary clearance mechanism and seeking to preserve the normal 
anatomic structures 7, 8. 
Imaging advances, increased understanding of the anatomy and the 
pathophysiology of chronic sinusitis, and image-guided surgery have 
allowed the surgeons to perform more complex procedures with increased 
safety.  
 
 
Indications 
Endoscopic sinus surgery is most commonly performed for inflammatory 
and infectious sinus disease. The most common indications for endoscopic 
sinus surgery are as follows: 
 
• Chronic sinusitis refractory to medical treatment 
 
• Recurrent sinusitis 
 
• Nasal polyposis 
 
• Antrochoanal polyps 
 
• Sinus mucoceles 
 
• Excision of selected tumors 
 
• Cerebrospinal fluid (CSF) leak closure 
 
• Orbital decompression (e.g., Graves ophthalmopathy) 
 
• Optic nerve decompression 
 
• Dacryocystorhinostomy (DCR) 
 
• Choanal atresia repair 
 
• Foreign body removal 
 
• Epistaxis control 
 
 
FESS is a delicate and time consuming procedure. It is performed routinely 
under general anesthesia. Can also be done under local anesthesia. 
Anesthesiologists have to plan the technique in such a way that will facilitate 
the operating team for achieving a bloodless field for better visualization of 
the intranasal structures and minimize intra operative bleeding, because even 
minimal bleeding can obstruct the view of the operating endoscope. Hence 
comes the role of hypotensive anesthesia.
Dexmedetomidine, an imidazole compound, is the pharmacologically active 
Dextroisomer of medetomidine, and is the most selective central α2 -
adrenoceptor agonist available clinically.  
 
 
Dexmedetomidine offers beneficial pharmacological properties, providing 
dose dependent sedation, analgesia, sympatholysis and anxiolysis without 
relevant respiratory depression. The dominant action of adrenoceptor α2 
agonists with low and clinically recommended concentrations is 
hypotension7. Now a day Dexmedetomidine has been used for controlled 
hypotension in middle ear as well as nasal endoscopic surgeries. The 
advantage of dexmedetomidine over routinely used agent like nitroglycerine 
is it will not cause reflex tachycardia. 
CHAPTER IV 
PHARMACOLOGY OF THE STUDY DRUGS 
 
Dexmedetomidine 9
 
 
It is a highly selective α2-adrenergic agonist that produces sedation, 
hypnosis and analgesia.
 
History 
The initiation for the use of α2 agonists in anesthesia resulted from 
observations made in patients during anesthesia who were receiving 
clonidine therapy. Dexmedetomidine was introduced in clinical practice in 
the United States in 1999. It was approved by the FDA only as a short-term 
(<24 hours) sedative for mechanically ventilated adult ICU patients. 
Dexmedetomidine is now being used off-label outside of the ICU in various 
settings. 
 
Pharmacological profile 
It is a highly selective α2-adrenergic agonist. It shows a high ratio of 
specificity for the α2 receptor (α2/α1 1600:1) compared with clonidine 
(α2/α1 200:1), making it a complete α2 agonist Dexmedetomidine belongs 
to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is 
freely soluble in water. 
Metabolism and Pharmacokinetics 
Dexmedetomidine has rapid redistribution. The half life is 6min. 
Dexmedetomidine is 94% protein bound   and its concentration ratio 
between whole blood and plasma is 0.66.  
It is extensively metabolized in the liver.  It undergoes conjugation (41%), n-
methylation (21%), or hydroxylation followed by conjugation. The inactive 
metabolites excreted in urine and feces. 
The elimination half-life of Dexmedetomidine is 2 to 3 hours, with a 
context- sensitive half-time ranging from 4 minutes after a 10-minute 
infusion to 250 minutes after an 8-hour infusion. No accumulation after 
infusions 12-24 h. Pharmacokinetics similar in young adults and elderly. 
 
Pharmacology  
It is a selective α2- adrenoreceptor agonist. Its action is unique and different. 
Three subtypes of α2 adrenoreceptors have been described in humans: α2A, 
α2B, and α2C .The α2A adrenoreceptors are present in the periphery where 
as α2B, and α2C are in the brain and spinal cord. Postsynaptically located α2 
adrenoreceptors produce vasoconstriction where as presynaptic α2 
adrenoreceptors inhibit the release of norepinephrine, potentially attenuating 
the vasoconstriction.
 
 
 
The overall response to α2 adrenoreceptor agonists is related to the 
stimulation of α2 adrenoreceptors located in the CNS and spinal cord. The 
α2 agonist produces their sedative-hypnotic effect by an action on α2 
receptors in the locus caeruleus and an analgesic action at α2 receptors 
within the locus caeruleus and within the spinal cord. 
 
Effects on the Central Nervous System 
Sedation 
The α2 agonists act through the endogenous sleep-promoting pathways to 
exert their sedative effect. 
It produces unique sedative quality - someone be clinically sedated yet 
arousable. Patients sedated, remaining so when unstimulated. But when 
stimulated they are arousable, alert, and able to respond without becoming 
uncomfortable. 
 It‘s also observed that they would quickly return to their sleep-like state. 
This characteristic allows for “daily wake up” tests to be done in a safe 
fashion. 
Despite sound levels of sedation with dexmedetomidine, there is limited      
respiratory depression, providing wide safety margins. 
Analgesia 
The analgesic effects of dexmedetomidine are complex. Alpha2 agonists do 
have an analgesic effect when injected via the intrathecal or epidural route. 
The primary site of analgesic action is thought to be the spinal cord. 
Systemic use of dexmedetomidine shows narcotic sparing. In the 
postoperative ICU setting, narcotic requirements were reduced by 50% when 
patients were receiving a dexmedetomidine.
In human pain studies, the results of systemically administered 
Dexmedetomidine are inconsistent. Modest reductions in pain were observed. 
In the clinical setting, when pain is likely to occur, if dexmedetomidine is to 
be used, the addition of a narcotic seems warranted. 
Other Central Nervous System Effects 
Dexmedetomidine in animal models of incomplete cerebral ischemia and 
reperfusion reduces cerebral necrosis and improves neurologic outcome by 
reducing the intracerebral catecholamine outflow and the reduction of the 
excitatory neurotransmitter glutamate during injury. 
Dexmedetomidine also is able to reduce muscle rigidity after high-dose 
opioid administration. 
Effects on the Respiratory System 
 
Dexmedetomidine at concentrations producing significant sedation reduces 
minute ventilation, but retains hypercapnic ventilatory response. The 
changes in ventilation appeared similar to those observed during natural 
sleep. Dexmedetomidine has been implicated in blocking histamine-induced 
bronchoconstriction in dogs. 
Effects on the Cardiovascular System 
The basic effects of α2 agonists on the cardiovascular system are decreased 
heart rate; decreased systemic vascular resistance; and indirectly decreased 
myocardial contractility, cardiac output, and systemic blood pressure. 
 
The hemodynamic effects of a bolus of Dexmedetomidine in humans have 
shown a biphasic response- an initial increase in blood pressure (22%) and 
decrease in heart rate (27%) from baseline that occurred at 5 minutes after 
injection (probably due to the vasoconstrictive effects of dexmedetomidine 
when stimulating peripheral α2 receptors). Heart rate return to baseline by 
15 minutes, and blood pressure decrease 15% below baseline by 1 hour. 
 
The incidence of hypotension and bradycardia may be related to the 
administration   of a loading dose. Omitting the loading dose or not giving 
more than 0.4 µg/kg reduces the incidence of hypotension. Giving the 
loading dose over 20 minutes also minimizes the transient hypertension. 
Dosage and administration 
Dexmedetomidine is supplied in a 2-mL ampoule, 100 mcg/ml. 
 
Dexmedetomidine must be diluted in 0.9% sodium chloride to achieve the 
required concentrations prior to administration. To prepare the infusion, 
withdraw 2 ml of dexmedetomidine and add to 48 ml of 0.9% sodium 
chloride injection to a total of 50 ml. The target concentration is 4 µg /ml.  
 Loading dose -0.5µg-1µg/kg over 10 min.  
Maintenance -0.3µg-0.7µg/kg/hr. 
Uses 
Dexmedetomidine has been approved as a short-term sedative for adult 
intubated patients in the ICU. Given its well-documented beneficial effects 
of anxiolysis, sedation, analgesia, and sympatholysis with minimal 
respiratory depression, it has been used in various other clinical scenarios.
1. Intensive Care Unit 
 
Dexmedetomidine has following advantages for sedation in mechanically 
ventilated postoperative patients. 
Decreased   requirement for opioids (>50%) when dexmedetomidine is used 
for sedation compared with propofol or benzodiazepines.   
Providing adequate sedation with minimal respiratory depression—can be 
used when weaning patients from the ventilator. 
Dexmedetomidine has been successfully used in the treatment of withdrawal 
of narcotics, benzodiazepines, alcohol, and recreational drugs 
 
2. Anesthesia 
a) As a premedicant, dexmedetomidine, at IV doses of 0.33 to 0.67 µg/kg 
given 15 minutes before surgery, seems efficacious, while minimizing the 
cardiovascular side effects of hypotension and bradycardia. Within this dose 
range dexmedetomidine reduces the requirement of thiopentone, volatile 
anesthetics and attenuates hemodynamic response to endotracheal  
intubation. 
 
b) IM injection (2.5 µg/kg) with or without fentanyl 45 to 90min before 
surgery provide angiolysis, reduced response to intubation, smaller volatile 
anesthetic requirements, and decreased incidence postoperative shivering. 
 c) Dexmedetomidine is used as a premedication 10 minutes before general 
surgery for cataract removal, intraocular pressure is decreased (33%), 
catecholamine secretion is reduced, perioperative analgesic requirements are 
less, and recovery is more rapid. 
 
d) Dexmedetomidine used for securing the airway with a fiberoptic 
intubation 
 
e) Dexmedetomidine has been used for sedation for monitored anesthesia 
care in gynecological, urological, burns patients, trauma patients, pediatric 
patients10, and in obese, OSA patients. 
 
f) Sedation during regional anesthesia. 
 
g) Dexmedetomidine also useful as anesthetic adjuvant in Bariatric surgery, 
Sleep apnea patients, Craniotomy aneurysm, AVM [hypothermia] ,Cervical 
spine surgery, Off-pump CABG, Vascular surgery, Thoracic surgery, 
Conventional CABG, Spine surgery, evoked potential study, Head  
Injury, Burns, Trauma. 
h) Dexmedetomidine has also been found to be an effective drug for 
premedication before i.v regional anesthesia11as it reduces patient anxiety, 
sympathoadrenal responses, and opioid analgesic requirements
Contraindications 
• Infusion over 24 hours. 
• In obstetric procedures, cesarean section deliveries, as the safety has not 
been studied. 
• Patients with pre-existent severe bradycardia and related 
bradydysrhythmias (e.g., advanced heart block). 
• Patients with impaired ventricular functions (ejection fraction <30%). 
• Patients who are hypovolemic or hypotensive. 
• Patient with raised intracranial tension. 
Antidote 
All effects of dexmedetomidine could be antagonized easily by 
administering the alpha 2-adrenoceptor antagonist atipamezole 12. 
ISOFLURANE 
Isoflurane (1-chloro-2, 2, 2-trifluoroethyl difluoromethyl ether) is 
halogenated ether used for inhalation anaesthesia. 
Physical properties13
-Molecular weight 184 g 
-Boiling point (at 1 atm): 48.5 °C 
-Density (at 25 °C): 1.496 g/mL 
-MAC: 1.17  
-Vapour pressure: 238 mm Hg 31.7 kPa (at. 20°C) 
-Blood: Gas Partition coefficient: 1.46 
-Oil: Gas Partition coefficient: 91 
Isoflurane is a non inflammable volatile annesthetic with a pungent ethereal 
odour.Although it is a chemical isomer of enflurane, it has different 
physicochemical properties.  
 Mechanism of Action of Inhaled Anesthetics 14 
Inhaled anesthetics act in different ways at the level of the central nervous 
system. They may disrupt normal synaptic transmission by interfering with 
the release of neurotransmitters from presynaptic nerve terminal (enhance or 
depress excitatory or inhibitory transmission), by altering the re-uptake of 
neurotransmitters, by changing the binding of neurotransmitters to the post 
synaptic receptor sites, or by influencing the ionic conductance change that 
follows activation of the post-synaptic receptor by neurotransmitters. Both, 
pre- and postsynaptic effects have been found. The high correlation between 
lipid solubility and anesthetic potency suggests that inhalation anesthetics 
have a hydrophobic site of action. Inhalation agents may bind to both 
membrane lipids and proteins. 
 
The Meyer-Overton theory describes the correlation between lipid solubility 
of inhaled anesthetics and MAC and suggests that anesthesia occurs when a 
sufficient number of inhalation anesthetic molecules dissolve in the lipid cell 
membrane. The Meyer-Overton rule postulates that the number of molecules 
dissolved in the lipid cell membrane and not the type of inhalation agent 
causes anesthesia. 
Mullins expanded the Meyer-Overton rule by adding the so-called Critical 
Volume Hypothesis. He stated that the absorption of anesthetic molecules 
could expand the volume of a hydrophobic region within the cell membrane 
and subsequently distort channels necessary for sodium ion flux and the 
development of action potentials necessary for synaptic transmission. 
The protein receptor hypothesis postulates that protein receptors in the 
central nervous system are responsible for the mechanism of action of 
inhaled anesthetics. This theory is supported by the steep dose response 
curve for inhaled anesthetics. 
 
Another theory describes the activation of Gamma-Amino Butyric Acid 
(GABA) receptors by the inhalation anesthetics. Volatile agents may 
activate GABA channels and hyperpolarize cell membranes. In addition, 
they may inhibit certain calcium channels and therefore prevent release of 
neurotransmitters and inhibit glutamate channels. Volatile anesthetics share 
therefore common cellular actions with other sedative, hypnotic or analgesic 
drugs. 
Pharmacokinetics: 
Uptake and distribution of inhaled anesthetics 14
A series of partial pressure gradients, beginning at the vaporizer of the 
anesthetic machine, continuing in the anesthetic breathing circuit, the 
alveolar tree, blood, and tissue will ensure the forward movement of the gas. 
The principal objective of that movement is to achieve equal partial 
pressures on both sides of each single barrier. The alveolar partial pressure 
governs the partial pressure of the anesthetic in all body tissues; they all will 
ultimately equal the alveolar partial pressure of the gas. After a short period 
of equilibration the alveolar partial pressure of the gas equals the brain 
partial pressure. Alveolar partial pressure can be raised by increasing minute 
ventilation, flow rates at the level of the vaporizer and by using a non-
rebreathing circuit. 
 
Isoflurane has a blood/gas partition coefficient of 1.4. This means that if the 
gas is in equilibrium the concentration in blood will be 1.4 times higher than 
the concentration in the alveoli. A higher blood gas partition coefficient 
means a higher uptake of the gas into the blood and therefore a slower 
induction time. It takes longer until the equilibrium with the brain partial 
pressure of the gas is reached. 
A higher cardiac output removes more volatile anesthetic from the alveoli 
and therefore lowers the alveolar partial pressure of the gas. The agent might 
be rapidly distributed within the body but the partial pressure in the arterial 
blood is lower. It will take longer for the gas to reach equilibrium between 
the alveoli and the brain. Therefore, a high cardiac output prolongs induction 
time. 
 
The alveolar to venous partial pressure difference reflects tissue uptake of 
the inhaled anesthetics.  Isoflurane has a brain/blood coefficient of 1.6 
meaning that if the gas is in equilibrium the concentration in the brain will 
be 1.6 times higher than the concentration in the blood. All inhalation 
anesthetics have high fat/blood partition coefficients. This means that most 
of the gas will bind to fatty tissue as times goes by. The partial pressure of 
the gas in fatty tissue will rise very slowly. Inhalation anesthetics stored in 
such tissue in obese patients may delay awakening at the end of anesthesia. 
Isoflurane shows very low solubility in blood and body tissues. Thus its 
partial pressure (concentration) in alveolar gas or arterial blood rises to 50% 
of the inspired partial pressure (concentration) within 4-8 minutes of the start 
of its inhalation, and to 60% within 15 minutes. 
Throughout maintenance of anesthesia, a high proportion of the Isoflurane 
inspired is eliminated by the lungs. When administration is stopped and 
inspired concentration becomes zero, the bulk of the remaining Isoflurane is 
eliminated unchanged from the lungs. In keeping with its low solubility, 
recovery from Isoflurane anesthesia in man is rapid. 
 
Effect on cardio vascular system 
Isoflurane causes minimal cardiac depression in vivo. Cardiac output is 
maintained by a rise in heart rate due to partial preservation of carotid 
baroreflexes. Isoflurane dilates coronary arteries, particularly if its 
concentration is abruptly increased, although it is not nearly as potent a 
dilator as nitroglycerine or adenosine. 
 
Effect on respiratory system 
Respiratory depression during isoflurane anesthesia resembles that of other 
volatile anesthetics, except that tachypnoea is less pronounced. The net 
effect is a more pronounced fall in minute ventilation. Despite a tendency to 
irritate upper airway reflexes, isoflurane is considered a good bronchodilator, 
but may not be as potent a bronchodilator as halothane. 
 
Effect on renal system 
Like other inhalational anesthetic agents, isoflurane decreases renal blood 
flow, glomerular filtration rate and urinary output transiently but hepatic 
oxygen supply is better maintained with isoflurane than halothane or 
enflurane. 
 
Metabolism 
Biotransformation of Isoflurane is significantly less than that of Enflurane or 
Halothane. Human biotransform a small fraction of Isoflurane administered. 
In man about 0.2% of the Isoflurane administered, is evident as recoverable 
metabolites (fluoride and organic fluorine), with approximately 50% of these 
excreted in the urine, the principal metabolite being trifluoracetic acid.  
Although serum fluoride levels may rise, nephrotoxicity is extremely 
unlikely even in the presence of enzyme inducers. Prolonged sedation (>24 
hours at 0.1-0.6%) of critically ill patients has resulted in elevated plasma 
fluoride levels without evidence of renal impairment. 
 
 
 
 
USES 
Induction: 
As Isoflurane has a mild pungency, inhalation should usually be preceded by 
the choice of a short-acting barbiturate, or other intravenous induction agent, 
to prevent coughing.  
Alternatively, Isoflurane with oxygen or an oxygen/nitrous oxide mixture 
may be administered. It is recommended that induction with Isoflurane be 
initiated at a concentration of 0.5%. Concentrations of 1.5-3.0% usually 
produce surgical anesthesia in 7-10 minutes. Blood pressure decreases 
during induction but this may be compensated by surgical stimulation. 
 
Maintenance: 
Adequate anesthesia for surgery may be sustained with an inspired 
Isoflurane concentration of 1.0% - 2.5% in an oxygen/70% nitrous oxide 
mixture. Additional inspired Isoflurane (0.5% - 1%) will be required with 
lower nitrous oxide levels, or when Isoflurane is given with oxygen alone or 
air/oxygen mixtures. Blood pressure decreases during maintenance 
anesthesia in relation to the depth of anesthesia. That is, blood pressure is 
inversely related to the Isoflurane concentration. Provided there are no other 
complicating factors this is probably due to peripheral vasodilatation. 
Cardiac rhythm remains stable. Excessive falls in blood pressure may be due 
to the depth of anesthesia and in such circumstances can be corrected by 
reducing the inspired Isoflurane concentration. 
Controlled hypotension  
Used to produce controlled hypotension either alone or in combination with 
other drugs.
In studies on humans and animals, isoflurane decreased blood pressure by 
decreasing SVR, whereas cardiac output was maintained constantly at 
clinically relevant concentrations of the anesthetic15 
In healthy young people, 2 to 3 % isoflurane decreases MAP by reducing 
SVR. 
 In older or chronically hypertensive patients, similar concentrations of 
isoflurane may also decrease cardiac output. For these individuals, 
combining a moderate concentration of isoflurane with agents that tend to 
maintain cardiac output would be more appropriate than using high 
concentrations of isoflurane alone. 
Isoflurane appears to offer certain advantages over other techniques 
commonly used to induce hypotension16 At lower cerebral perfusion 
pressures (<30 mmHg), the cerebral metabolic rate for oxygen was better 
preserved, suggesting cerebral protection. Isoflurane also favorably 
influenced the global cerebral oxygen supply/demand ratio in humans 
having a MAP of 50 mmHg17 
Recovery: 
The concentration of Isoflurane can be reduced to 0.5% at the start of 
closing the operation wound, and then to 0% at the end of surgery. After 
discontinuation of all anesthetics, the airways of the patient should be 
ventilated several times with oxygen 100% until complete recovery. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
REVIEW OF LITERATURE 
This study was designed to evaluate the effect of Dexmeditomidine infusion 
on the requirement of Isoflurane to maintain mean arterial pressure of 60-70 
mmHg. Literature was reviewed to analyze the existence of similar studies. 
1. Mohammad Maroof, et al,18 in their study on ‘Dexmedetomidine Is a 
Useful Hypotensive Adjunct during Middle Ear Surgery under General 
Anesthesia’ recruited 42 ASA I or II adult patients scheduled for elective 
Middle Ear Surgery and were randomly divided into 2 equal groups. 
Group-I: Received 10-15 min before induction of anesthesia, placebo bolus 
and infusion of saline at a rate similar to DEX in group-II. 
Group-II: Received 10-15 min prior to induction of anesthesia 1 µg/ kg iv 
bolus DEX diluted in 10 ml of normal saline over 10 min. anesthesia was 
maintained with 60% nitrous oxide + 40% oxygen + isoflurane titrated to 
achieve a mean arterial pressure [MAP] 30% below the control value (value 
taken after premedication). Isoflurane and DEX/ SAL infusion was stopped 
8-10 min prior to end of surgery. They  analyzed the isoflurane requirement, 
quality of surgical field , awakening time and concluded that DEX infusion 
aids in achieving a targeted reduction in MAP, better blood less field, faster 
awakening and reduced Isoflurane requirement in patients undergoing 
middle ear surgery. 
2. Durmus M, et al, 19 in their study on ‘Effect of dexmedetomidine on 
bleeding during tympanoplasty or septorhinoplasty’ recruited 40 adult 
patients randomly assigned them to receive either a bolus dexmedetomidine 
or placebo before induction of anesthesia followed by infusion. They 
maintained mean arterial pressure around 60-80mmHg. They analyzed 
Perioperative mean arterial pressure, heart rate, time to extubation and time 
to awakening. They found that propofol dose required for induction, 
intraoperative fentanyl, isoflurane requirement and bleeding were low in 
dexmedetomidine group than control and concluded that dexmedetomidine 
is a useful adjuvant to decrease bleeding when a bloodless surgical field is 
requested. 
3. Guldem Turan, et al20 in their study on ‘Comparison of 
dexmedetomidine, Remifentanil and Esmolol in Controlled Hypotensive 
Anesthesia’ recruited 70 adult patients undergoing tympanoplasty into three 
groups. Group D (n=26) Dexmedetomidine 1 µg /kg (10 min) loading, 0.2-
0.7µg/kg/h infusion Group R (n=21) Remifentanil 0.2-0.5 µg/ kg/min  
Group E (n=23) Esmolol 500 µg/kg(1min) loading, 50-300µg 
/kg/ min infusion. They maintained anesthesia with desflurane 3-6% 
They  analyzed the quality of surgical field, Spontaneous eye opening time, 
extubation time, verbal response time, cooperation and orientation time and 
concluded  that dexmedetomidine, remifentanil and esmolol may be  used 
for controlled hypotension during tympanoplasty operations in respect of 
intraoperative bleeding, recovery and adverse effects. 
4.Hilal Ayoglu, et al 21 in their study on ‘Effectiveness of dexmedetomidine 
in reducing bleeding during septoplasty and tympanoplasty operations ’ 
recruited 80 adult patients  undergoing tympanoplasty and septoplasty and            
were divided them into four groups. Dexmedetomidine (D) was 
administered to Group SD(20) and Group TD(20) first as a bolus dose of one 
µg /kg, then intraoperative maintenance of  dexmedetomidine 0.7 µg/kg/ 
hour. Groups S(20) and T(20) (controls) were given identical amount of 
saline.  They used thiopentone 6mg/kg , rocuronium  0.6mg/kg for induction 
and sevoflurane for maintenance. They were analyzed intraoperative blood 
loss,hemodynamic parameters, fentanyl requirements and concluded that 
dexmedetomidine reduces bleeding, intraoperative fentanyl consumption and 
improve visibility of the field during septoplasty.Dexmedetomidine also 
significantly decrease fentanyl need in tympanoplasty but the decrease in 
intraoperative bleeding was not significant. 
5. Iclal Ozdemir Kol, et al, 22 in their study on ‘Controlled Hypotension 
with Desflurane Combined with Esmolol or Dexmedetomidine During 
Tympanoplasty in Adults’ recruited 48 ASA I & II adult patients into two 
groups (Esmolol and Dex). Esmolol group a loading dose of esmolol was 
infused intravenously over 1 minute at 1 mg/kg, followed by a maintenance 
rate of 0.4 to 0.8 mg/kg/h. In the dexmedetomidine group, a loading dose of 
dexmedetomidine was infused intravenously over 10 minutes at a rate of 1 
µg/kg, followed by a maintenance rate of 0.4 to 0.8 µg/kg/h. The infusion 
rates were then titrated to maintain mean arterial pressure (MAP) of 65 to 75 
mm Hg. General anesthesia was maintained with desflurane 4% to 6%. They 
analyzed the amount of blood loss in the surgical field, recovery time and 
tolerability in adult patients. They concluded that both esmolol and 
dexmedetomidine, combined with desflurane, provided an effective and 
well-tolerated method for achieving a bloodless surgical field with 
controlled hypotension in these patients undergoing tympanoplasty. Esmolol 
was associated with significantly shorter extubation and recovery times and 
significantly less postoperative sedation compared with dexmedetomidine. 
6.Farah Nasreen , et al, 23 in their study on Dexmedetomidine used to 
provide hypotensive anesthesia during middle ear surgery recruited 42 
patients into two groups ( Dex and NS).Group I  received NS equal to 
dexmedetomidine and Group II received 1mcg/kg dex as bolus  10-15 min 
before induction followed by infusion of 0.5mcg/kg/hr. They titrated 
halothane to maintain mean arterial pressure 30% below the control value. 
They observed that a statistically significant reduction in the percentage of 
halothane requirement in group II  (1.3 ± 0.4%) in comparison to   group I 
(3.1 ± 0.3%). Patients receiving DEX infusion had a better surgical field. 
The mean awakening time was significantly reduced in patients of Group II 
(9.1 ± 2.7 min) when compared to patients of Group I (12.8 ± 2.2 min) and 
concluded that DEX can be safely used to provide hypotensive anesthesia 
during middle ear surgery. 
7. Lawrence CJ,et al, 24  in their study on ‘Effects of a single pre-operative 
dexmedetomidine dose on isoflurane requirements and peri-operative 
haemodynamic stability ’ placebo-controlled study investigated the effect of 
a single pre-induction intravenous dose of dexmedetomidine2 
micrograms.kg-1 on anesthetic requirements and peri-operative 
hemodynamic stability in 50 patients undergoing minor orthopaedic and 
general surgery. The mean (SD) intra-operative isoflurane concentration was 
lower in the dexmedetomidine-treated patients than controls (0.01 (0.03)% 
compared to 0.1 (0.1)%; p = 0.001) .They found that the haemodynamic 
response to tracheal intubation and extubation was reduced in the 
dexmedetomidine group. The intra-operative heart rate variability; 
postoperative analgesic and anti-emetic requirements and peri-operative 
serum catecholamine concentrations were also lower in the 
dexmedetomidine group. Hypotension and bradycardia occurred more 
frequently after dexmedetomidine. 
8. Khan ZP, et al, 25 in their study on ‘Effects of dexmedetomidine on 
isoflurane requirements in healthy volunteers’  concluded that 
dexmedetomidine decreases isoflurane requirements in a dose-dependent 
manner and reduced heart rate, systolic and diastolic arterial pressures. 
Sedation and slight impairment of cognitive function persisted for several 
hours after anesthesia and the end of infusion of dexmedetomidine. 
Isoflurane did not appear to influence the pharmacokinetics of 
dexmedetomidine. 
9.Aantaa R, et al, 26 in their study on ‘ Reduction of the minimum alveolar 
concentration of isoflurane by dexmedetomidine ’  recruited 49 patients  
scheduled for abdominal hysterectomy and randomly allocated to receive 
either a placebo infusion (n = 16) or a two-stage infusion of 
dexmedetomidine with target plasma concentration of 0.3 ng/ml (n = 17) or 
0.6 ng/ml (n = 16). The study drug infusion was commenced 15 min before 
induction. The end-tidal concentration of isoflurane for each patient was 
predetermined according to the "up-down" method of Dixon, and it was 
maintained for at least 15 min before the patient's response to skin incision 
was assessed. They found the MAC of isoflurane was 0.85% end-tidal in the 
control group, 0.55% end-tidal with the low dose of dexmedetomidine, and 
0.45% end-tidal with the high dose of dexmedetomidine. 
10. Bayazit Dikmen, et al, 27 in their study on ‘Dexmedetomidine for 
Controlled Hypotension in Middle Ear Surgery with Low-Flow Anesthesia ’ 
Forty patients undergoing middle ear surgery were studied. In Group D 
(n=20), Dexmedetomidine (0.1µg/kg/min for 10 minutes) was administered 
before induction and continued with a rate between 0.2-0.7 µg/kg/h and 
Group S(n=20) received normal saline with a rate of 50 ml.h-1. Infusions 
were stopped at the end of microsurgery.  Anesthesia was induced with 
thiopental and vecuronium bromide. Maintenance of anesthesia was 
achieved by 1.5 % isoflurane delivered in mixture of O2 and N2O 4.4 
L.min-1 for 10 min and then flow rate was reduced to 1 L.min-1 and 
isoflurane concentration was increased to 2 %. Haemodynamic parameter, 
quality of the surgical field and surgeon satisfaction were evaluated. They 
concluded that   Dexmedetomidine was effective in inducing consistent and 
sustained controlled hypotension in low-flow anesthesia during middle ear 
microsurgery. 
11.Richa F, et al, 28 in their study on ‘Comparison between 
dexmedetomidine and remifentanil for controlled hypotension during 
tympanoplasty’ recruited 24 patients into two groups (Dex and 
Remifentanil). They found that infusion of dexmedetomidine, at the doses 
(0.4-0.8 mcg/ kg/hr) used in this study, was less effective than remifentanil 
in achieving controlled hypotension, good surgical field exposure condition 
and surgeon’s satisfaction during tympanoplasty. 
12. Berrin Isik, et al, 29 in their study on ‘The Effects of Adrenergic 
Receptor Agonist Dexmedetomidine on Hemodynamic Response in Direct 
Laryngoscopy ’ recruited 40 patients scheduled for direct laryngoscopy 
under general anesthesia. The patients were randomly divided into two 
groups, Intramuscular 0.05 µg /kg midazolam (Group M) or intravenous 1 
µg /kg dexmedetomidine (Group D) was applied. Heart Rate and mean 
arterial pressure (MAP) were measured before premedication and noted 
down as control values. Preoperative hemodynamic parameters, recovery 
times and sedation levels of both groups were compared. They concluded 
that dexmedetomidine premedication in direct laryngoscopy procedures 
controls hypertension and tachycardia more efficiently without prolonged 
recovery time than midazolam premedication. 
13.Hulaya Basar, et al, 30 in their study on ‘The effects of preanesthetic, 
single-dose dexmedetomidine on induction, hemodynamic, and 
cardiovascular parameters ’ recruited 40 patients scheduled for elective 
cholecystectomy and divided into two groups to receive 0.5 µg 
kg−1 dexmedetomidine (group D, n = 20) or saline solution (group C, n = 20). 
Anesthesia was induced with thiopental sodium and vecuronium, and 
anesthesia was maintained with 4% to 6% desflurane. They analyzed  Mean 
arterial pressure (MAP), heart rate (HR), ejection fraction (EF), end-diastolic 
index (EDI), cardiac index (CI), and stroke volume index (SVI) were 
recorded at 10-minute intervals. The times for patients to “open eyes on 
verbal command” and postoperative Aldrete recovery scores were also 
recorded. They concluded that a single dose of dexmedetomidine given 
before induction of anesthesia decreases thiopental requirements without 
serious hemodynamic effects or any effect on recovery time. 
14. Goksu.S,et al, 31 in their study on ‘Effects of dexmedetomidine infusion 
in patients undergoing functional endoscopic sinus surgery under local 
anesthesia ’ Sixty-two patients who were planned to undergo functional 
endoscopic sinus surgery under local anesthesia were included in this study 
and divided into Dex and NS groups. Dexmedetomidine bolus intravenous 
infusion (an initial loading dose of 1 µg kg-1 given for a 10-min period 
followed by 0.7 µg/ kg/h) was administered to the treatment group. They 
concluded that dexmedetomidine provides analgesia, adequate sedation and 
surgical comfort without adverse effects for patients undergoing functional 
endoscopic sinus surgery under local anesthesia. 
15. Damla Guclu Guven, et al, 32 in their study on ‘Evaluation of Outcomes 
in Patients given Dexmedetomidine in Functional Endoscopic Sinus 
Surgery  ’ Forty patients who underwent FESS were enrolled in this  study. 
In the DEX group, conscious sedation was induced with an infusion of 1 
µg/kg of DEX bolus, followed by an infusion of DEX at 0.2 µg/kg per hour. 
A control group was given identical amounts of saline solution. During the 
procedure, hemodynamic data were recorded. The patients evaluated their 
pain on a visual analog scale (VAS). Intraoperative bleeding was rated on a 
6-point scale for evaluation of operative field visibility. They observed that 
the intraoperative bleeding, hemodynamic stability, and VAS scores were 
better and the side effects were less frequent in the DEX group. 
16. Alp Gurbet , et al, 33 in their study on ‘Intraoperative infusion of 
dexmedetomidine reduces perioperative analgesic requirements ’ Fifty 
women were randomly assigned to two groups. Group D (n = 25) received a 
loading dose of dexmedetomidine 1 µg·kg–1 iv during induction of 
anesthesia, followed by a continuous infusion at a rate of 0.5 µg·kg–1·hr–1 
throughout the operation. Group P (n = 25) received a volume-matched 
bolus and infusion of placebo (0.9% saline). They analyzed perioperative 
hemodynamics and post operative pain score and morphine requirement. 
They observed that Continuous iv dexmedetomidine during abdominal 
surgery provides effective postoperative analgesia, and reduces 
postoperative morphine requirements without increasing the incidence of 
side effects. 
17.Uzumcugil F, et al, 34 in their study on ‘Comparison of 
dexmedetomidine-propofol vs. fentanyl-propofol for laryngeal mask 
insertion ’ recruited 52 patients posted for urological procedures divided into 
two groups. Group F received 1 kg(-1) µg fentanyl (in 10 mL normal saline) 
and Group D received µg kg(-1) dexmedetomidine. They observed that jaw 
mobility, coughing or movement and other events such as spontaneous 
ventilation, breath holding, expiratory stridor and lacrimation. They 
concluded that Dexmedetomidine, when used before propofol induction 
provides successful laryngeal mask insertion comparable to fentanyl, while 
preserving respiratory functions more than fentanyl 
18. Yezdan Firat, et al, 35 in their study on ‘The effect of dexmedetomidine 
on middle ear  pressure ’ recruited 60 patients into two groups ( Dex and 
NS). The alteration of middle ear pressure values from baseline were 
analyzed in both groups. In which the differences from the baseline were 
statistically significant in both groups. They concluded that 
Dexmedetomidine should be preferred in middle ear surgery requiring good 
surgical field visibility and normal middle ear pressure. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI 
AIM 
To Evaluate the effect of  Dexmedetomidine infusion on the requirement of 
Isoflurane to produce controlled hypotension(mean arterial pressure of 60-
70mmHg), quality of bloodless surgical field, duration of surgery and the 
awakening time in patients undergoing Functional Endoscopic Sinus 
Surgery(FESS). 
 
CHAPTER VII 
MATERIALS AND METHODS 
This study was conducted after obtaining approval from ethical committee 
and patients consent. 
Study Design 
Prospective randomized control study 
Patient selection 
50 ASA I Patients age 18-60 years   diagnosed   having chronic   sinusitis 
scheduled for FESS under general anesthesia were divided into two groups. 
Exclusion Criteria 
1. Hypertensive patients. 
2. H/o Cerebro-vascular accident / Transient ischaemic attack. 
3. IHD. 
4. Poor respiratory reserve. 
5. Significant hepatic or renal disease. 
6. Hypersensitivity to study drugs. 
7. Patients who are not willing to participate in the study 
Materials 
1. Perfusor compact-Syringe infusion pump. 
2. Inj.Dexmedetomidine 2 ml amp, Normal saline. 
3. Disposable 50 ml syringe. 
4. Extension tube. 
5. Weighing machine. 
6. Monitors – ECG, NIBP, SPO2 
Methodology 
50 patients with the above criteria were divided into two equal groups.
Group D: Received bolus dose of Dexmedetomidine 1 µg /kg over ten min 
before induction followed by infusion of 0.5 µg /kg/hr. (2ml of 
dexmedetomidine was diluted with 48ml of NS making a solution of 4 µg 
/ml) 
Group C: Received equal amount of Normal Saline.  
Preoperative investigations reports like Hb%, Blood Urea, Serum  Creatinine, 
Platelets, Clotting time, Bleeding time were recorded. 
On arriving to the operating room monitors were connected and baseline 
vital parameters were noted. Two peripheral intravenous line with 18 G IV 
Cannula one for IV infusion another for study drug were started. Preloading 
was done with 10 ml/kg of balanced salt soulations. 
Premedicated  with Inj. Glycopyrrolate 5 mcg/kg +Inj. Fentanyl 2 mcg/kg. 
The study drugs were started according to the group. 
 
Then anesthesia was induced with Inj.Propofol 2mg/kg + Inj. Vecuronium 
0.1 mg/kg and intubated with appropriate size endotracheal tube. Throat 
packed with saline socked pack. 
 
Anesthesia was maintained with 66% N2O + 33% O2 + IPPV with titrated 
dose of isoflurane and Vecuronium. 
 
The mean arterial pressure was maintained around 60-70mmHg by titrating 
the intra operative isoflurane percentage. The isoflurane concentration was 
recorded every five min   and averaged for analysis. 
Intra-operative hypotension was managed by 
 
1. IV fluids LR/NS 200 ml 
2. Taper down isoflurane 
3. Ephedrine 3mg i.v. bolus 
Intra-op Tachycardia (HR > 150 bpm) controlled by  i.v. Metoprolol 1-5 mg  
Intra-op bradycardia ( HR < 50 bpm) managed by, 0.3 mg atropine  every 2 
–3 min till it reached above 60 beats/ min
Intra-op Arrhythmias: 
If haemodynamically stable, continue with the study but with close and 
increased monitoring. 
If unstable, abandon hypotension, volume resuscitate and manage 
accordingly. 
 
Both study drug and isoflurane were stopped 10-15 min prior to end of 
surgery. Inj. Ondansetron 4mg was given intrapoeratively. The throat pack 
was removed at the end of the endoscopic procedure. 
The residual neuromuscular blockade was reversed with inj.neostigmine 50 
mcg/kg+inj. Glcopyrrolate 10mcg/kg and was extubated. The awakening 
time in min (clearly telling their name) from the time of extubation were 
recorded. 
 
Patients were observed in the recovery room for nausea & vomiting, 
sedation score  and then monitored in the postoperative ward. Both groups 
were hemodynamically stable and none showed any adverse reactions like 
reflex hypertension, nausea and vomiting. 
Parameters studied 
1. Heart rate 
2. Systolic blood pressure 
3. Diastolic blood pressure 
4. Mean arterial pressure. 
5. Requirement of isoflurane percentage 
6. Intraoperative   problems (hypotension, hypertension, arrythmias,             
tachycardia, bradycardia  and ischemia 
7. Duration of surgery. 
8. Quality of operating field . 
9. Awakening time. 
10. Ramsay sedation scale.  
Intraoperative surgical field was assessed by using Fromme-Boezaart scale 
as given below 
Surgical field grading: Fromme –Boezaart scale 
(Evaluation scale for bleeding of surgical field) 
Grade  O: No bleeding. 
Grade 1: Slight   bleeding-No suctioning of blood required. 
Grade 2: Slight   bleeding-Occasional suctioning required. Surgical field not 
threatened. 
Grade 3: Slight   bleeding-Frequent suctioning required. Bleeding threatens 
surgical field a few seconds after suction is removed. 
Grade 4: Moderate   bleeding- Frequent suctioning required. Bleeding 
threatens surgical field directly after suction is removed. 
Grade 5: Severe bleeding-Constant suctioning required. Bleeding appears 
faster than can be removed by suction. Surgical field   severely threatened 
and surgery impossible 
 
Postoperative sedation were assessed by following scale 
Ramsay Sedation Scale 
1   Patient is anxious and agitated or restless, or both 
2   Patient is cooperative, oriented and tranquil 
3   Patient responds to commands only 
4   Patient exhibits brisk response to light glabellar tap or loud auditory 
stimulus 
5   Patient exhibits a sluggish response to light glabellar tap or loud auditory 
stimulus 
6   Patient exhibits no response 
Data Management and Analysis 
The variables were entered into SPSS, version 15, statistical software for 
analysis. Statistical analysis was done by using descriptive statistics and 
cross tabulation. Mean and standard deviation were used to assess changes 
within and between the two groups. The difference in proportions is tested 
for statistical significance using non parametric chi-square test for variables 
measured on nominal scale. For variables measured on a continuous scale, 
student “t” Test was used. A p value of <0.05 was considered to be 
statistically significant.  
CHAPTER VIII 
OBSERVATION AND RESULTS 
DEMOGRAPHIC DATA 
TABLE I 
Age distribution 
Student  “t”test 
 Group  D Group C p-value 
No. of cases 25 25 
0.611 Mean 33.20 31.76 
S.D 9.574 10.325 
Range 18-53 18-55 
Not statistically significant 
AGE DISRIBUTION 
31
31.5
32
32.5
33
33.5
GROUP D GROUP C
Mean
The mean age between the comparison groups were almost similar.
 
The minimum age taken for the study was 18 and the maximum was 55. 
TABLE II 
Sex Distribution 
Chi-Square Test 
 Group  D Group C  
p-value Nos. % Nos. % 
Male 17 68 16 64  
1.000 Female 8 32 9 36 
Not statistically significant 
SEX DISTIBUTION 
0
2
4
6
8
10
12
14
16
18
GROUP D GROUP C
MALE
FEMALE
The male preponderance was forthcoming in all the study groups.  
However the distribution of sex among the groups was not statistically 
significant. 
TABLE III 
Weight Distribution 
Student “t” test 
 Group  D Group C p-value 
No. of cases 25 25  
0.331 Mean 59.04 57.40 
S.D 6.465 5.284 
Range 45-70 45-65 
Not statistically significant 
WEIGHT DISRIBUTION 
56.5
57
57.5
58
58.5
59
59.5
GROUP D GROUP C
MEAN
The mean distribution of cases by weight was observed to be not statistically 
significant between the two groups. 
TABLE IV 
Intraoperative hemodynamic parameters 
Student “t” test
Parameter Group  D Group C p-value 
Heart Rate 
Pre Induction 75.92±5.787 79.24±8.695 0.119 
Post Induction 71.68±6.830 76.48±9.417 0.045* 
Post Intubation 75.12±5.761 88.04±7.618 0.001* 
Avg. Intraop 58.44±2.873 75.84±6.472 0.001* 
Post Extubation 72.88±5.231 79.04±11.681 0.020* 
SBP 
Pre Induction 122.28±8.532 121.28±8.824 0.639 
Post Induction 105.96±10.597 114.88±13.486 0.012* 
Post Intubation 100.84±12.701 117.56±12.145 0.001* 
Avg. Intraop 91.16±1.864 93.40±3.440 0.006* 
Post Extubation 116.88±9.528 124.00±10.194 0.014* 
DBP 
Pre Induction 81.36±6.376 78.72±7.220 0.177 
Post Induction 69.44±7.896 71.60±11.365 0.439 
Post Intubation 65.04±8.039 78.40±11.236 0.001* 
Avg. Intraop 58.80±1.581 61.08±2.499 0.001* 
Post Extubation 77.24±8.686 80.76±9.701 0.183 
MAP 
Pre Induction 95.00±6.333 92.85±7.270 0.271 
Post Induction 81.61±8.058 86.03±11.064 0.113 
Post Intubation 76.97±9.217 91.45±11.066 0001* 
Avg. Intraop 69.72±1.400 71.80±2.566 0.001* 
Post Extubation 90.45±8.654 95.17±9.385 0.071 
 
*statistically significant 
Intraoperative Hemodynamic parameters 
Heart Rate 
0
10
20
30
40
50
60
70
80
90
100
PR
E I
ND
UC
RI
ON
PO
ST
 
IN
DU
CT
IO
N
PO
ST
 
IN
TU
BA
TI
ON
AV
G.
IN
TR
AO
P
PO
ST
 
EX
TU
BA
TI
ON
GROUP D
GROUP C
Pre induction heart rate was almost similar. No statistical difference (p-
0.119). But the heart rate after induction, after intubation and during 
intraoperative period was statistically significant which was lower in group 
D compared  to group C. 
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Regarding the systolic blood pressure both groups showed almost equal 
results in pre induction period. But the a systolic blood pressure after 
induction, after intubation and during intraoperative period was lower in 
group  D which was statistically significant. 
Diastolic Blood Pressure 
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The diastolic blood pressure was lower in group D after intubation and 
during the intraoperative period which was statistically significant.
Mean Arterial Pressure 
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Regarding the mean arterial pressure post intubation & average intra 
operative values were low in group D which was statistically significant. 
Other value like pre induction, post induction and post extubation were 
comparable in both and was not statistically significant. 
TABLE V 
Intraoperative Isoflurane requirement 
Student “t”test 
 Group  D Group C p-value 
No. of cases 25 25  
<0.001* Mean 0.387 1.783 
S.D 0.102 0.211 
Range 0.2-1.4 1-2.5 
*Statistically Significant 
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The average intra operative isoflurane requirement was low in  group 
D(0.387) Compared to group C(1.783).This was statistically significant 
(p- <0.001). 
 
TABLE VI 
Intraoperative adverse events 
Chi-Square Test 
Intraoperative 
problems 
Group  D Group C  
p-value Nos. % Nos. % 
Hyper 
tension 
YES 
NO 
0 
25 
0 
100 
0 
25 
0 
100 
- 
Hypo 
tension 
YES 
NO 
0 
25 
0 
100 
0 
25 
0 
100 
- 
Arrhythmia YES 
NO 
0 
25 
0 
100 
0 
25 
0 
100 
- 
Tachycardia YES 
NO 
0 
25 
0 
100 
0 
25 
0 
100 
- 
Bradycardia YES 
NO 
2 
23 
8 
92 
3 
22 
12 
88 
1.000 
Ischemia YES 
NO 
0 
25 
0 
100 
0 
25 
0 
100 
- 
Not statistically significant 
 
Intra operative problems such as hypertension, Hypotension, Arrhythmia, 
Tachycardia, Ischemia were not seen in any groups. Bradycardia was seen in 
two cases in group D and three cases in group C. This was not statistically 
significant (p-1.000) 
 
TABLE VII 
Effect of Study drug on duration of surgery 
Student “t”test
 Group  D Group C p-value 
No. of cases 25 25 
0.004* Mean 76.84 94.16 S.D 14.174 25.083 
Range 45-102 56-135 
* statistically significant 
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All patients underwent the same type of surgery. The duration of surgery 
was less with group D  when compared to group C which is statistically 
significant (P= 0.004). 
 
TABLE VIII 
Evaluation of the surgical field by surgeon 
Chi-Square Test
Fromme 
Boezzart Scale Group  D  Group C p-value 
No. of cases 25 25 
0.333 GRADE I 14 14 GRADE II 11 09 
GRADE III 00 02 
Not statistically significant 
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The surgical field grading was almost equal in two groups .Two patients in 
group C showed Grade III, none in group D. But this was not statistically 
significant. (P-0.333) 
TABLE IX 
Awakening Time 
Student “t”test
Group  D  Group C p-value 
No. of cases 25 25 
<0.001* Mean 5.12 9.72 S.D 1.691 1.100 
Range 3-10 8-12 
* statistically significant 
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The awakening time was low in  group D compared to C group which was  
statistically  significant.(p-0.001) 
 
TABLE X 
RAMSAY SEDATION SCALE 
Group  D  
Student “t”test
TIME IN MIN SCORE 2 SCORE 3 
15 MIN 15 10 
30 MIN 19 06 
45 MIN 25 00 
60 MIN 25 00 
Group C 
Student “t”test
TIME IN MIN SCORE 2 SCORE 3 
15 MIN 10 15 
30 MIN 18 07 
45 MIN 24 01 
60 MIN 25 00 
There was no significant difference in the sedation score. 
CHAPTER IX 
DISCUSSION 
To achieve controlled hypotension in functional   endoscopic  sinus surgeries 
either inhalation technique or intravenous technique are used routinely. If 
inhalational agents were used to provide   hypotensive   anesthesia large 
inspired concentration of the anesthetics was used than that required to 
produce surgical anesthesia. 
 
By   stimulating the pre synaptic alpha 2-adrenoceptors dexmedetomidine  
decreases  the nor epinephrine release  and causes fall   in blood pressure & 
heart rate .Because of this property Dexmedetomidine is now a days used as 
hypotensive agent in endoscopic surgeries. It also has an added advantage of 
analgesic property thus reducing   peri operative analgesic requirement. 
Hence this study was designed to evaluate the effect of dexmedetomidine on 
isoflurane requirement in achieving MAP of 60-70mmHg. 
 
Both the groups were comparable in demographic distribution, resting heart 
rate and blood pressure. 
 
Even though both the group received same mode of induction,  intubation 
response was less in dexmedetomidine group compared to control. This was   
comparable with result of  Berrin  Isik, et al,29  
 
Intra operative mean arterial pressure was maintained around 60-70mmHg 
by titrating isoflurane   percentage. The group C needed  more 
isoflurane(1.7±0.211) than group D(0.387±0.102)
.
This was statistically 
significant(p-<0.001). This finding concurred with the results of the study by 
Mohammad  Maroof, et al18, in their study on ‘Dexmedetomidine  is  a 
Useful  Hypotensive Adjunct during Middle Ear Surgery under General 
Anesthesia’. In their study  the mean isoflurane requirement in DEX group 
was 1.3±0.4 and in saline group was 3.1±0.3.The same result was observed  
by  Farah Nasreen , et al, 23.But they used halothane. 
 
The intra operative heart rate was found to be lower in group D. This finding 
concurred with the results of the study by Guldem Turan, et al20 and  
Durmus M, et al19 They found that  the heart rate was lower in DEX 
group .This finding also concurred with the results of Hilal Ayoglu, et al 21  
showed  DEX will not cause reflex tachycardia peri operatively. The average 
intra operative systolic  blood  pressure , diastolic blood pressure , mean 
arterial pressure were significantly lower in Dexmedetomidine group 
compared to control group. 
 
Regarding the intra operative adverse reaction 2 patients in  group D(8%) 
and 3 patients  in  group C(12%) developed  bradycardia. It was easily 
reversed by atropine 0.3mg IV single dose in both the groups. 
This was not statistically significant (p-1.000). Other intra operative 
problems like   hypertension , arrhythmias ,tachycardia, ischemia were not 
encountered in either of the groups. 
 
There was statistically significant difference in duration of surgery (p-.004) 
The mean duration of surgery in   group D was (76.84±14.174) In group C 
was (94.1±25.083). 
 The evaluation  of surgical field  was done by a surgeon blinded to the study 
drugs using  Fromme  Boezzart scale.  All patients in group D belonged to 
grade 2 and below and in group C to grade 3 and below, which denotes 
highly acceptable surgical field as far as the surgeon was concerned. 
Some studies showed  that the need for perioperative  analgesic requirement 
was lower in dex group(Durmus M, et Al19, Hilal Ayoglu et al,21 and  Iclal 
Ozdemir  Kol,et al, et al22).We haven’t analyzed this parameter. 
 The awakening time  in min (time required to tell clearly their name  from 
the end of tracheal extubation) was lower in  group D( 5.12±1.691) 
compared to group C(9.72±1.100)It was statistically significance(p-0.001).It 
concurred with the result of Mohammad Maroof, et al 16. They found  that 
the mean awakening time in dex group was 9.1±2.7 min and in NS group 
was 12.8±.2min.The intraoperative isoflurane consumption was 
comparatively more than our study ( in group D- 1.3Vs0.38, in group C( 3.1 
VS 1.7).This may be the reason the awakening time was prolonged in both 
the group in their study. 
 
Regarding the hemodynamic stability after extubation both group returned to 
their baseline values. 
 
In our study however, none of the patients in both the groups had nausea and 
Vomiting in the post operative period. This could be due to prophylactic 
administration   of inj. Ondansetron. 
 
There was no significant difference in the postoperative sedation score in 
both the   groups. 
CHAPTER X 
SUMMARY 
The prospective randomized control study aimed to evaluate the effect of 
Dexmedetomidine infusion on the requirement of Isoflurane to maintain a 
mean arterial pressure of 60-70mmHg, Quality of blood less surgical  field, 
duration of surgery and  awakening time in patients undergoing Functional 
Endoscopic Sinus Surgery(FESS) under general anaesthesia 
Important conclusions from this study include 
 1. Group D lowered intra operative blood pressure better than group C. 
2. Group D produced lower intraoperative   heart rate than group C. 
3. Intra operative isoflurane   requirement   was   low in group D compared 
to group C. 
4. Both the group provided better   visualization of the surgical field 
assessed  by the surgeon using Fromme Boezzart scale. 
5. The duration of surgery was low in Group D. 
6. The awakening time after extubation was also low in Group D  compared   
to Group C. 
7. There was no difference in postoperative sedation. 
 
CHAPTER XI 
CONCLUSION 
Dexmedetomidine infusion helps in achieving a targeted reduction in MAP, 
reduced intraoperative Isoflurane requirement, better blood less field, and 
faster awakening in patients undergoing Functional Endoscopic Sinus 
surgery. 
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MASTER CHART GROUP - C
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 VIOLET 32 F 56 66 106 67 80 NIL 68 96 65 75 1 77 110 70 83 1.4 75 106 55 72 1.8
2 PADMASHINI 48 F 50 82 128 76 93 NIL 84 109 63 78 1 93 124 79 94 1.4 87 122 77 92 1.6
3 SURENDRABABU 19 M 60 74 124 85 98 NIL 81 112 60 77 1 89 140 95 110 1.4 88 118 78 91 1.6
4 THANGAM 55 F 56 90 132 88 103 NIL 82 121 62 82 1 87 119 78 92 1.4 82 112 75 87 1.6
5 PRAKASH 28 M 60 76 124 83 97 NIL 70 107 71 83 1 90 99 66 77 1 80 107 77 87 1.6
6 RAMESH 35 M 60 75 128 83 98 NIL 74 117 79 92 1 94 121 83 96 1.2 79 93 64 74 1.2
7 SUDHAKAR 30 M 55 82 132 88 103 NIL 70 93 67 76 1 96 120 92 101 1.2 89 118 70 86 1.4
8 VEERAMUTHU 23 M 55 67 125 70 88 NIL 65 90 48 62 NIL 90 117 66 83 1 94 119 76 90 1.2
9 ANANDBABU 22 M 55 74 123 79 94 NIL 85 98 61 73 1 99 124 78 93 1.2 97 119 77 91 1.4
10 KAMARAJ 30 M 60 91 122 76 91 NIL 89 126 75 92 1 92 102 69 80 1.2 87 115 81 92 1.6
11 RAMAN 32 M 45 69 124 80 95 NIL 67 127 85 99 1 82 117 86 96 1.6 81 113 84 94 1.8
12 PADMANABHAN 34 M 65 81 128 84 99 NIL 72 121 62 82 1 89 120 82 95 1.4 89 115 71 86 1.6
13 SHANMUGAM 26 M 60 84 118 78 91 NIL 72 104 77 86 1 87 104 68 80 1.2 90 102 60 74 1.4
14 MIRNALINI 27 F 50 72 124 80 95 NIL 90 130 87 101 1 104 129 83 98 1.2 94 101 69 80 1.4
15 YUVARANI 18 F 55 94 108 74 85 NIL 69 110 67 81 1 80 124 87 99 1.2 82 102 68 79 1.4
16 KALAVATHI 29 F 53 98 113 81 92 NIL 72 102 68 79 1 95 108 78 88 1.2 81 96 70 79 1.4
17 ANANDAN 36 M 58 73 119 82 94 NIL 89 122 74 90 1 92 106 65 79 1.2 86 99 64 76 1.4
18 SHAJATHA 29 M 65 80 119 80 93 NIL 97 123 87 99 1 98 150 116 127 1.4 95 139 101 114 2
19 GOWERI 50 F 65 78 139 89 106 NIL 76 142 91 108 1 77 99 68 78 1.2 89 137 94 108 1.8
20 DINESH 24 M 60 93 108 64 79 NIL 68 126 56 79 1 82 108 74 85 1.2 87 113 77 89 1.4
21 SHANKAR 32 M 62 78 130 90 103 NIL 88 132 91 105 1 77 108 74 85 1.4 79 104 61 75 1.6
22 KAUSIKANTH 38 M 60 79 112 64 80 NIL 65 124 74 91 1 83 126 73 91 1.4 86 125 73 90 1.6
23 PONGUNDRAN 26 M 65 75 122 74 90 NIL 70 100 67 78 1 86 122 75 91 1.2 78 113 69 84 1.4
24 PREMA 53 F 55 68 105 75 85 NIL 66 122 84 97 1 75 119 81 94 1.2 68 128 87 101 1.6
25 RADHA 18 F 50 82 115 78 90 NIL 83 118 69 85 1 87 123 74 90 1.4 90 129 78 95 1.8
SL.NO NAME AGE SEX WEIGHT PRE INDUCTION POST INDUCTION POST INTUBATION 5 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 79 86 58 67 1.4 79 87 58 68 1.4 82 90 58 69 1.4 89 97 62 74 1.6 90 89 60 70 1.6 81 90 58 69 1.6
2 75 112 63 79 1.8 73 101 62 75 2 69 89 61 70 2 66 88 59 69 1.8 71 89 57 68 1.8 78 86 58 67 1.6
3 77 106 61 76 1.8 79 99 57 71 1.8 87 101 63 76 2 87 89 61 70 2 88 89 59 69 2 86 89 57 68 2
4 86 97 69 78 1.8 78 94 66 75 2 77 94 61 72 2 79 90 58 69 2 84 89 57 68 2 85 89 56 67 1.8
5 74 96 62 73 1.6 76 94 66 75 1.8 70 96 68 77 2 72 92 60 71 2 69 90 59 69 2 70 93 59 70 2
6 89 100 72 81 1.4 81 98 73 81 1.6 83 97 73 81 1.8 89 93 70 78 1.8 81 95 70 78 2 75 106 70 82 2.5
7 76 101 68 79 1.6 65 92 52 65 1.4 69 108 68 81 1.6 64 92 56 68 1.6 60 93 56 68 1.6 62 93 55 68 1.6
8 82 102 61 75 1.4 63 102 60 74 1.6 74 94 55 68 1.6 67 105 56 72 1.8 67 103 56 72 2 76 103 55 71 2
9 89 91 63 72 1.6 76 91 63 72 1.8 71 91 63 72 2 72 91 61 71 2 74 91 60 70 2 75 91 59 70 2
10 83 113 78 90 1.8 85 113 72 86 2 71 112 64 80 2.5 76 89 61 70 2 79 89 59 69 2 73 85 57 66 2
11 80 113 82 92 2 71 103 73 83 2.5 62 94 67 76 2.5 57 87 62 70 2 56 86 56 66 2 55 85 55 65 2
12 78 90 59 69 1.6 79 89 59 69 1.6 78 89 57 68 1.6 76 88 60 69 1.6 81 87 59 68 1.6 82 89 60 70 1.6
13 78 89 59 69 1.4 75 87 58 68 1.4 69 91 59 70 1.6 78 90 59 69 1.6 79 89 56 67 1.6 78 89 57 68 1.6
14 86 98 67 77 1.6 93 85 53 64 1.4 93 109 66 80 1.6 93 109 66 80 1.8 85 92 53 66 1.8 78 92 57 69 1.8
15 83 99 68 78 1.8 88 93 62 72 1.8 80 94 67 76 2 86 89 64 72 2 82 90 60 70 2 84 87 58 68 2
16 82 97 70 79 1.6 83 97 70 79 1.8 83 95 70 78 2 86 84 51 62 1.8 84 89 52 64 1.6 87 89 54 66 1.6
17 68 90 58 69 1.4 72 89 57 68 1.4 79 88 58 68 1.2 82 91 62 72 1.4 65 90 58 69 1.4 69 89 57 68 1.4
18 95 111 67 82 2 89 99 56 70 2 88 96 57 70 2 89 94 56 69 2 79 88 53 65 2 82 87 53 64 1.8
19 94 134 89 104 2 93 124 84 97 2 92 99 62 74 2.5 93 97 60 72 2.5 90 93 62 72 2.5 90 89 61 70 2.5
20 83 102 68 79 1.6 85 111 70 84 1.8 81 105 70 82 2 82 85 57 66 2 68 88 58 68 2 69 90 60 70 2
21 83 90 61 71 1.6 85 101 66 78 1.8 82 97 60 72 2 78 90 58 69 2 79 88 58 68 2 81 90 58 69 2
22 88 112 67 82 2 74 95 64 74 2 78 91 59 70 2 69 89 57 68 2 71 89 59 69 2 75 86 58 67 1.8
23 83 106 69 81 1.6 87 95 61 72 1.6 77 97 62 74 1.8 69 97 62 74 2 65 89 58 68 2 69 88 59 69 2
24 66 131 85 100 1.8 68 118 76 90 2 70 114 64 81 2.5 73 91 59 70 2 71 89 59 69 2 72 89 57 68 2
25 89 118 75 89 1.8 87 109 69 82 2 88 105 67 80 2.5 89 96 62 73 2.5 86 88 60 69 2.5 84 88 56 67 2
SL.NO 20 MIN 25 MIN10 MIN 15 MIN 30 MIN 35 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 85 86 59 68 1.6 85 86 57 67 1.6 83 88 59 69 1.4 80 98 58 71 1.6 85 93 62 72 1.8 83 88 58 68 1.8
2 72 86 56 66 1.6 73 89 61 70 1.6 76 90 62 71 1.8 79 88 59 69 1.8 74 88 57 67 1.8 74 89 57 68 1.8
3 78 90 58 69 2 76 87 55 66 2 82 89 57 68 2 75 90 56 67 2 72 109 71 84 NIL 71 110 65 80 NIL
4 75 88 58 68 1.8 78 91 59 70 1.8 74 92 60 71 2 79 89 56 67 2 82 89 59 69 2 87 90 58 69 2
5 82 90 58 69 2 75 87 56 66 2 75 87 58 68 2 71 87 57 67 1.8 67 87 59 68 1.8 69 89 59 69 1.8
6 80 90 62 71 2.5 85 89 61 70 2.5 89 88 60 69 2.5 88 88 59 69 2 87 88 58 68 2 89 90 60 70 2
7 61 93 55 68 1.6 59 92 54 67 1.4 59 98 54 69 1.4 57 90 55 67 1.4 53 90 55 67 1.4 55 91 60 70 1.4
8 79 100 55 70 2 82 96 56 69 2 81 97 56 70 2 83 98 58 71 2 88 94 58 70 2 88 94 57 69 2
9 72 90 58 69 2 70 88 57 67 1.8 66 87 58 68 1.8 64 87 57 67 1.8 60 87 56 66 1.6 61 86 55 65 1.6
10 76 88 59 69 2 75 89 57 68 2 73 89 56 67 1.8 72 89 57 68 1.6 71 91 62 72 1.8 72 89 59 69 1.8
11 54 85 55 65 1.8 52 85 55 65 1.8 65 89 70 76 2 65 89 68 75 2 68 86 64 71 2 69 85 62 70 2
12 84 92 62 72 1.8 85 90 60 70 1.8 78 90 58 69 1.8 76 88 57 67 1.8 71 89 55 66 1.6 76 88 59 69 1.6
13 69 90 58 69 1.6 67 90 60 70 1.8 71 89 59 69 1.8 73 89 58 68 1.8 74 85 57 66 1.6 79 85 55 65 1.4
14 76 92 55 67 1.8 77 92 55 67 1.8 76 92 56 68 1.8 78 92 57 69 1.8 74 91 57 68 1.8 72 100 72 81 NIL
15 88 86 55 65 1.8 89 93 62 72 2 89 92 60 71 2 89 90 59 69 2 86 90 59 69 2 89 87 57 67 2
16 80 87 55 66 1.6 78 88 55 66 1.6 76 90 56 67 1.6 71 89 59 69 1.6 69 89 56 67 1.6 70 96 56 69 NIL
17 78 86 56 66 1.2 76 89 61 70 1.4 69 91 59 70 1.6 70 87 57 67 1.6 67 89 57 68 1.6 69 90 58 69 1.6
18 78 86 53 64 1.8 79 84 52 63 1.6 79 85 51 62 1.4 76 83 50 61 1.2 70 83 50 61 1 72 84 51 62 1
19 85 88 61 70 2.5 85 90 60 70 2.5 83 88 59 69 2 80 88 58 68 2 85 102 67 79 2.5 83 90 59 69 2
20 67 90 58 69 2 80 88 57 67 2 78 87 56 66 1.8 83 88 59 69 1.8 85 91 59 70 2 81 88 60 69 2
21 82 88 58 68 1.8 86 91 59 70 1.8 84 89 59 69 1.8 76 88 56 67 1.8 77 89 59 69 1.8 74 88 57 67 1.6
22 72 91 59 70 2 70 88 58 68 2 81 88 57 67 2 78 90 58 69 2 82 91 60 70 NIL 87 96 61 73 NIL
23 70 86 58 67 2 67 90 58 69 2 65 89 56 67 1.8 78 90 58 69 1.6 81 88 57 67 1.6 81 91 62 72 1.8
24 72 86 57 67 1.8 68 90 57 68 1.8 67 88 59 69 1.6 69 91 60 70 1.8 75 90 59 69 1.8 73 90 60 70 NIL
25 85 89 59 69 2 85 91 62 72 2.5 83 90 59 69 2 80 89 57 68 2 85 90 55 67 2 83 90 58 69 2
SL.NO 40 MIN 45 MIN 50 MIN 55 MIN 60 MIN 65 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 71 90 58 69 1.8 69 88 57 67 1.8 75 86 56 66 1.4 78 89 57 68 1.4 82 90 58 69 1.4 84 94 58 70 NIL
2 78 88 57 67 1.6 68 89 61 70 NIL 69 91 62 72 NIL 76 94 62 73 NIL
3
4 85 87 59 68 2 85 89 57 68 2 76 86 57 67 1.8 78 85 57 66 1.8 76 88 56 67 1.6 70 89 59 69 1.6
5 69 85 59 68 1.8 66 88 59 69 1.8 66 90 59 69 1.8 65 88 59 69 1.8 66 90 59 69 1.8 65 86 58 67 1.6
6 85 89 61 70 2 84 89 60 70 2 93 90 61 71 2 94 89 60 70 2 89 90 60 70 2 75 107 71 83 NIL
7 53 92 61 71 1.6 53 91 60 70 1.6 53 90 60 70 1.6 52 90 60 70 1.6 75 123 90 101 NIL 89 134 90 105 NIL
8 76 93 56 68 1.8 73 105 57 73 2 75 91 59 70 2 77 92 58 69 2 78 89 59 69 1.8 83 106 64 78 NIL
9 61 85 55 65 1.6 59 85 55 65 1.4 57 84 55 65 1.4 55 85 55 65 1.2 56 88 56 67 1.2 55 88 57 67 1.2
10 76 89 58 68 1.8 78 88 57 67 1.6 87 89 61 70 1.8 79 88 59 69 1.6 76 88 61 70 NIL 77 88 58 68 NIL
11 68 85 62 70 2 70 85 61 69 2 71 84 61 69 2 71 83 62 69 2 70 83 62 69 2 68 82 60 67 1.8
12 76 89 61 70 1.6 72 88 60 69 NIL 75 95 61 72 NIL 87 115 66 82 NIL
13 77 87 62 70 1.6 73 89 62 71 1.8 78 89 59 69 1.8 67 89 57 68 1.8 65 89 61 70 2 69 90 60 70 2
14 72 100 72 81 NIL 74 104 73 83 NIL 73 110 79 89 NIL
15 89 86 56 66 1.8 86 83 53 63 1.6 82 86 68 74 1.8 83 91 64 73 2 88 89 61 70 2 88 89 59 69 2
16 72 98 60 73 NIL 85 98 62 74 NIL
17 65 89 55 66 1.4 72 89 56 67 1.4 73 88 58 68 1.4 65 89 59 69 1.4 64 89 58 68 1.4 62 88 56 67 1.4
18 70 86 51 63 0.8 67 87 51 63 0.8 67 87 53 64 0.8 65 88 52 64 0.6 63 97 60 72 0.8 65 96 60 72 0.8
19 71 95 64 74 NIL 69 93 62 72 NIL 75 121 82 95 NIL
20 78 89 57 68 1.8 76 89 59 69 1.8 76 88 60 69 1.8 78 89 61 70 1.8 70 90 61 71 NIL 69 103 74 84 NIL
21 68 90 58 69 1.6 67 88 60 69 1.6 69 89 61 70 1.8 66 89 59 69 1.8 64 89 58 68 1.6 67 88 60 69 1.6
22 82 97 62 74 NIL 78 106 74 85 NIL
23 79 89 59 69 1.8 77 90 57 68 1.8 78 91 58 69 1.8 77 90 59 69 NIL 79 92 63 73 NIL 86 109 65 80 NIL
24 68 96 69 78 NIL 65 109 68 82 NIL 67 125 87 100 NIL
25 87 88 57 67 2 85 89 58 68 2 82 90 57 68 2 80 89 59 69 NIL 78 93 60 71 NIL 77 112 67 82 NIL
SL.NO 70 MIN 75 MIN 80 MIN 85 MIN 90 MIN 95 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 74 96 58 71 NIL 76 94 64 74 NIL 70 96 66 76 NIL
2
3
4 78 90 60 70 1.8 73 90 58 69 1.8 71 89 57 68 NIL 73 91 62 72 NIL 87 97 62 74 NIL
5 66 86 58 67 1.6 65 90 58 69 1.6 65 87 57 67 1.4 68 89 57 68 1.4 65 84 56 65 1.2 69 86 58 67 NIL
6 75 132 92 105 NIL 75 123 78 93 NIL 78 116 77 90 NIL
7
8 73 121 69 86 NIL 85 119 80 93 NIL
9 55 88 57 67 1.2 53 89 57 68 1.2 56 87 57 67 1 54 86 57 67 1 51 87 58 68 NIL 66 113 79 90 NIL
10 78 91 62 72 NIL
11 66 82 60 67 1.8 65 85 61 69 1.8 64 86 62 70 1.8 60 88 60 69 1.8 54 96 71 79 NIL 54 102 73 83 NIL
12
13 76 88 57 67 1.8 76 89 59 69 1.8 78 88 56 67 NIL 76 88 60 69 NIL 76 90 60 70 NIL 68 97 65 76 NIL
14
15 87 90 59 69 2 87 90 57 68 2 89 93 60 71 2 91 87 54 65 2 92 86 53 64 1.8 89 87 54 65 1.8
16
17 58 90 57 68 1.4 50 90 58 69 1.4 78 90 60 70 1.6 82 89 61 70 1.6 79 90 58 69 1.4 81 89 58 68 NIL
18 61 95 59 71 1 68 96 58 71 1.2 65 94 58 70 1.2 67 92 58 69 1.2 63 91 56 68 1.2 63 88 55 66 1
19
20 79 133 84 100 NIL
21 71 95 62 73 NIL 72 91 60 70 NIL 75 98 66 77 NIL 78 100 60 73 NIL
22
23 85 122 89 100 NIL
24
25 78 128 94 105 NIL
SL.NO 100 MIN 105 MIN 110 MIN 115 MIN 120 MIN 125 MIN
AFTER EXTUBATION
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP
1 62 118 78 91
2 76 118 70 86
3 74 118 72 87
4 92 108 74 85
5 68 88 60 69 NIL 69 87 61 70 NIL 68 89 61 70 NIL 83 110 77 88
6 68 130 80 97
7 69 103 68 80
8 65 124 66 85
9 76 128 98 108 NIL 87 125 81 96
10 68 118 70 86
11 54 106 75 85 NIL 52 108 75 86 NIL 64 141 99 113
12 81 127 83 98
13 92 115 74 88
14 89 124 83 97
15 80 85 54 64 NIL 64 97 68 78 NIL 64 97 68 78 NIL 84 128 76 93
16 86 124 88 100
17 78 92 63 73 NIL 84 123 84 97 NIL 72 120 84 96
18 68 91 56 68 1 72 91 53 66 1 74 91 56 68 NIL 75 101 74 83 NIL 103 142 108 119 NIL 113 149 110 123
19 74 124 86 99
20 72 120 81 94
21 83 132 84 100
22 72 136 89 105
23 89 136 83 101
24 89 128 87 101
25 72 124 76 92
SL.NO 130 MIN 150 MIN140 MIN135 MIN 145 MIN
HYPER TENSION HYPO TENSION ARRYTHMIAS ISCHEMIA TACHYCARDIA BRADYCARDIA
1 N N N N N N 94 1
2 N N N N N N 85 2
3 N N N N N N 56 1
4 N N N N N N 112 2
5 N N N N N N 130 1
6 N N N N N N 95 1
7 N N N N N N 72 1
8 N N N N N N 75 2
9 N N N N N Y 120 2
10 N N N N N N 102 2
11 N N N N N Y 120 1
12 N N N N N N 82 1
13 N N N N N N 110 1
14 N N N N N N 65 1
15 N N N N N N 133 3
16 N N N N N N 62 2
17 N N N N N Y 130 2
18 N N N N N N 135 1
19 N N N N N N 60 1
20 N N N N N N 92 1
21 N N N N N N 109 1
22 N N N N N N 66 3
23 N N N N N N 96 2
24 N N N N N N 68 1
25 N N N N N N 85 2
DURATION OF SURGERY FROMME BOEZART SCALESL.NO INTRAOP EVENTS
15 30 45 60
1 10 3 3 2 2
2 11 3 3 2 2
3 10 3 2 2 2
4 9 2 2 2 2
5 10 3 3 2 2
6 10 3 2 2 2
7 8 2 2 2 2
8 9 3 2 2 2
9 8 2 2 2 2
10 10 3 2 2 2
11 10 3 2 2 2
12 11 3 3 2 2
13 9 2 2 2 2
14 9 2 2 2 2
15 10 3 2 2 2
16 8 2 2 2 2
17 11 3 3 2 2
18 11 3 2 2 2
19 12 3 3 3 2
20 9 2 2 2 2
21 10 3 2 2 2
22 9 2 2 2 2
23 8 2 2 3 2
24 10 2 2 2 2
25 11 3 3 3 2
RAMSAY SEDATION SCALEAWAKENING TIMESL.NO
MASTER CHART GROUP - D
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 VASUKI 30 F 50 74 130 74 93 NIL 67 96 69 78 1 72 90 60 70 0.8 65 89 58 68 0.6
2 MOHAN 42 M 62 80 120 88 99 NIL 75 100 60 73 1 66 92 60 71 0.8 65 92 59 70 0.8
3 MUTHU 22 M 60 85 132 89 103 NIL 81 126 82 97 1 84 128 79 95 1.2 73 102 60 74 1.2
4 LALITHA 38 F 63 86 112 81 91 NIL 82 104 72 83 1 86 100 65 77 1 73 90 61 71 0.6
5 MANIVEL 26 M 56 70 130 90 103 NIL 64 106 54 71 1 76 112 63 79 1.2 72 100 63 75 1.4
6 ARUN 26 M 66 68 135 81 99 NIL 63 125 71 89 1 81 134 84 101 1.2 85 100 63 75 1.2
7 DRAVIDASELVAN 42 M 65 81 140 82 101 NIL 76 93 64 74 1 84 112 79 90 1.2 82 99 65 76 1.2
8 SANGETHA 28 F 52 76 121 79 93 NIL 65 98 70 79 1 76 92 60 71 1 64 90 58 69 0.8
9 KAMARAJ 30 M 58 81 108 75 86 NIL 70 100 66 77 1 65 90 60 70 0.8 63 92 64 73 0.8
10 KARTHIKEYAN 50 M 65 72 118 72 87 NIL 63 106 67 80 1 76 98 60 73 1 67 96 55 69 0.6
11 DEVI 24 F 45 70 124 89 101 NIL 83 121 86 98 1 74 104 69 81 1.2 72 95 60 72 1.2
12 ASHOK 36 M 55 75 138 94 109 NIL 69 118 87 97 1 77 106 76 86 1.2 65 96 62 73 1.2
13 KUMAR 36 M 70 76 130 87 101 NIL 66 122 73 89 1 71 96 68 77 1.2 64 95 57 70 1
14 SASIKUMAR 35 M 65 85 120 82 95 NIL 71 104 71 82 1 85 90 60 70 0.8 68 90 59 69 0.8
15 VATCHALA 32 F 65 82 124 87 99 NIL 85 96 70 79 1 72 90 59 69 0.8 73 90 58 69 0.6
16 UTHARA 19 F 50 84 122 81 95 NIL 69 114 80 91 1 68 96 61 73 1.2 65 90 59 69 1
17 SUDHAKAR 30 M 60 69 116 80 92 NIL 80 96 61 73 1 76 121 78 92 1.4 75 112 60 77 1.4
18 JAGADESHVARAN 34 M 62 79 109 73 85 NIL 68 106 67 80 1 71 113 69 84 1.2 67 90 62 71 1.2
19 DURAIRAJ 40 M 65 77 122 88 99 NIL 69 99 63 75 1 72 90 60 70 0.8 62 89 56 67 0.6
20 LAKSHMIKANTH 38 M 65 69 113 69 84 NIL 72 106 69 81 1 74 94 63 73 1 72 90 59 69 0.8
21 GANESAN 48 M 60 75 114 80 91 NIL 70 90 68 75 1 73 90 59 69 0.8 64 90 59 69 0.6
22 KARTHIK 18 M 60 69 119 75 90 NIL 65 119 74 89 1 74 90 60 70 0.8 66 91 59 70 0.8
23 PREMA 53 F 50 70 122 78 93 NIL 68 99 62 74 1 71 95 60 72 1 67 90 60 70 0.6
24 SUJATHA 35 F 52 72 120 81 94 NIL 82 96 63 74 1 82 93 60 71 1 61 89 56 67 0.8
25 SARAVANAN 18 M 55 73 118 79 92 NIL 69 109 67 81 1 72 105 54 71 1 66 97 60 72 1.2
SL.NO NAME AGE SEX WEIGHT 5 MINPOST INDUCTION POST INTUBATIONPRE INDUCTION
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 55 90 59 69 0.6 55 99 62 74 0.8 55 90 61 71 0.8 56 86 58 67 0.8 60 86 51 63 0.4 54 84 51 62 0.2
2 55 89 58 68 0.6 55 88 61 70 0.6 55 89 56 67 0.4 56 86 58 67 0.2 60 86 51 63 NIL 54 84 51 62 NIL
3 65 92 58 69 1 58 89 55 66 0.6 56 88 56 67 0.6 58 89 2 31 0.6 60 86 57 67 0.4 59 84 54 64 0.2
4 67 89 59 69 0.6 66 89 58 68 0.4 62 88 58 68 0.4 56 96 58 71 0.6 57 86 55 65 0.4 58 88 54 65 0.2
5 55 90 61 71 1.4 55 89 62 71 1 55 89 61 70 0.8 56 96 58 71 0.8 60 86 51 63 0.4 54 84 51 62 0.2
6 55 95 60 72 1.2 55 90 60 70 1 55 89 61 70 0.8 56 86 58 67 0.6 60 86 51 63 0.4 54 87 54 65 0.2
7 65 90 58 69 0.6 63 90 58 69 0.4 63 81 52 62 0.2 59 83 53 63 0.2 59 86 53 64 0.2 57 89 55 66 NIL
8 58 89 60 70 0.6 55 90 56 67 0.4 55 88 52 64 0.2 56 88 53 65 NIL 54 86 52 63 NIL 54 89 56 67 NIL
9 62 90 59 69 0.6 59 89 60 70 0.6 62 90 59 69 0.6 56 96 58 71 0.8 60 89 59 69 0.6 56 89 57 68 0.4
10 61 89 58 68 0.6 57 89 59 69 0.6 55 88 57 67 0.4 56 86 52 63 NIL 60 86 55 65 NIL 58 89 58 68 NIL
11 68 84 57 66 0.6 72 86 56 66 0.4 69 89 60 70 0.4 66 86 60 69 0.4 69 89 61 70 0.4 66 89 59 69 0.4
12 55 90 60 70 1.2 55 89 60 70 1 55 88 60 69 0.8 58 86 57 67 0.6 60 86 56 66 0.4 59 87 58 68 0.4
13 62 90 59 69 0.6 60 89 58 68 0.6 62 91 57 68 0.4 60 93 58 70 0.4 56 88 60 69 0.4 54 80 54 63 NIL
14 61 89 60 70 0.6 56 90 59 69 0.6 55 89 61 70 0.6 56 92 58 69 0.6 60 86 59 68 0.4 56 84 53 63 0.2
15 65 84 57 66 0.4 59 81 56 64 0.2 57 86 54 65 0.2 55 87 58 68 0.2 53 88 59 69 0.2 54 87 59 68 0.2
16 58 89 59 69 0.8 55 86 58 67 0.6 60 90 61 71 0.8 56 86 58 67 0.6 58 86 58 67 0.4 54 84 56 65 0.2
17 59 90 59 69 0.8 55 88 57 67 0.6 55 89 60 70 0.6 56 88 58 68 0.4 60 87 56 66 0.4 54 89 55 66 0.2
18 63 91 58 69 1 61 86 53 64 0.8 55 89 60 70 0.8 56 86 56 66 0.8 58 86 58 67 0.6 54 89 55 66 0.4
19 55 88 59 69 0.6 55 87 60 69 0.4 55 86 53 64 0.2 56 92 58 69 0.2 57 90 56 67 0.2 61 89 60 70 0.4
20 66 90 58 69 0.6 65 89 58 68 0.4 63 85 56 66 0.4 59 83 53 63 0.2 59 86 53 64 0.2 57 89 55 66 NIL
21 60 89 59 69 0.6 61 86 58 67 0.4 57 90 56 67 0.2 56 90 58 69 0.2 58 90 57 68 0.2 58 89 58 68 0.2
22 60 90 58 69 0.6 60 89 58 68 0.6 63 82 52 62 0.2 59 82 52 62 NIL 59 85 52 63 NIL 58 86 53 64 NIL
23 62 89 63 72 0.8 58 86 61 69 0.8 55 88 59 69 0.6 56 89 58 68 0.6 60 86 55 65 0.4 54 86 55 65 0.4
24 55 88 58 68 0.6 61 90 63 72 0.8 57 89 58 68 0.6 56 87 58 68 0.4 59 88 55 66 0.4 57 89 56 67 0.4
25 67 90 59 69 0.8 66 90 60 70 0.8 64 90 62 71 1 68 89 55 66 0.8 63 85 53 64 0.6 66 88 52 64 0.4
SL.NO 10 MIN 15 MIN 20 MIN 25 MIN 30 MIN 35 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 51 92 62 72 0.4 51 93 57 69 0.4 51 99 55 70 0.4 52 92 57 69 0.2 51 101 55 70 0.2 52 93 57 69 0.2
2 51 90 62 71 NIL 56 100 57 71 0.2 55 99 55 70 0.2 53 96 56 69 0.2 57 97 55 69 NIL 60 98 59 72 NIL
3 61 92 58 69 0.2 62 93 55 68 0.2 59 99 55 70 0.4 54 90 58 69 0.4 56 89 57 68 0.2 56 90 57 68 0.2
4 55 90 57 68 0.2 53 88 59 69 0.2 51 89 55 66 0.2 52 86 55 65 0.2 54 90 57 68 0.2 56 91 59 70 NIL
5 51 92 62 72 0.2 51 121 57 78 0.4 51 99 55 70 0.4 52 99 55 70 0.2 51 101 55 70 0.2 52 100 57 71 0.4
6 55 89 58 68 0.2 56 90 57 68 0.2 53 89 56 67 0.2 57 88 59 69 0.2 56 102 60 74 NIL 63 100 62 75 NIL
7 57 100 61 74 0.2 57 92 60 71 0.2 57 96 63 74 0.4 57 90 59 69 0.4 56 97 63 74 0.6 55 90 58 69 0.4
8 56 91 60 70 0.2 54 90 57 68 0.2 55 89 55 66 0.2 58 90 59 69 0.2 57 90 58 69 0.2 56 90 60 70 0.2
9 57 88 58 68 0.4 54 89 57 68 0.4 57 92 56 68 0.4 58 89 54 66 0.2 57 90 59 69 0.2 59 89 57 68 0.2
10 51 92 62 72 0.2 56 90 57 68 0.2 55 92 58 69 0.2 56 91 55 67 0.2 56 89 56 67 0.2 60 89 58 68 0.2
11 68 89 63 72 0.6 72 89 60 70 0.6 71 91 60 70 0.6 70 89 58 68 0.4 66 86 59 68 0.4 63 91 60 70 0.4
12 56 90 55 67 0.2 58 89 60 70 0.2 59 90 56 67 0.2 57 89 59 69 0.2 56 86 58 67 0.2 58 92 60 71 NIL
13 52 81 55 64 NIL 53 87 55 66 NIL 53 85 55 65 NIL 54 87 55 66 NIL 56 93 62 72 0.2 55 90 60 70 0.2
14 55 90 57 68 0.2 54 91 57 68 0.2 56 96 59 71 0.4 61 92 55 67 0.4 63 89 57 68 0.2 62 90 58 69 NIL
15 56 96 64 75 0.4 53 96 63 74 0.6 57 87 62 70 0.6 54 87 62 70 0.6 55 87 60 69 0.6 59 88 64 72 NIL
16 57 92 62 72 0.4 62 89 57 68 0.4 60 89 58 68 0.4 55 90 59 69 0.2 56 91 57 68 0.2 59 90 58 69 NIL
17 61 90 56 67 0.2 56 89 57 68 0.2 60 90 59 69 0.2 62 90 60 70 0.2 63 91 62 72 NIL 61 90 60 70 NIL
18 58 88 59 69 0.4 56 89 57 68 0.4 59 90 55 67 0.4 56 86 54 65 0.2 54 87 55 66 NIL 59 87 56 66 NIL
19 56 90 57 68 0.2 60 89 59 69 0.2 58 90 55 67 0.2 54 89 60 70 0.2 57 90 58 69 0.2 58 89 59 69 NIL
20 57 96 61 73 0.2 57 89 62 71 0.4 57 89 59 69 0.4 57 87 60 69 0.4 56 95 61 72 0.6 55 90 58 69 0.6
21 55 92 63 73 0.4 56 89 57 68 0.4 62 90 55 67 0.2 57 88 55 66 0.2 59 89 55 66 0.2 56 90 62 71 0.4
22 56 89 55 66 NIL 56 89 57 68 NIL 57 91 60 70 NIL 61 101 69 80 NIL 62 97 64 75 NIL
23 58 88 59 69 0.4 60 90 57 68 NIL 62 97 60 72 NIL 62 108 62 77 NIL
24 58 90 56 67 0.4 56 90 57 68 0.4 54 86 55 65 0.2 56 88 54 65 NIL 57 90 60 70 0.2 55 89 58 68 0.2
25 61 91 57 68 0.4 64 92 64 73 0.6 68 90 58 69 0.4 65 91 57 68 0.4 65 88 59 69 0.4 64 87 58 68 0.4
SL.NO 50 MIN 55 MIN 60 MIN45 MIN40 MIN 65 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 52 92 58 69 0.2 52 91 59 70 0.2 56 100 59 73 NIL 58 98 62 74 NIL 58 98 63 75 NIL 60 100 63 75 NIL
2 59 99 62 74 NIL
3 52 89 58 68 0.2 58 90 59 69 NIL 65 96 64 75 NIL 65 97 63 74 NIL
4 56 96 60 72 NIL 62 100 68 79 NIL
5 52 89 58 68 0.2 52 91 59 70 0.2 52 90 60 70 0.4 54 100 64 76 NIL 52 106 75 85 NIL 52 119 86 97
6 65 104 62 76 NIL
7 58 89 60 70 0.4 56 82 50 61 NIL 54 84 52 63 NIL 58 86 54 65 0.2 67 114 83 93 NIL 69 118 76 90 NIL
8 55 89 61 70 0.2 57 92 59 70 0.4 59 89 55 66 0.4 56 88 54 65 0.2 54 89 59 69 0.2 56 90 59 69 NIL
9 60 90 62 71 0.4 56 96 55 69 0.4 59 94 58 70 0.4 61 94 56 69 0.4 60 92 59 70 NIL 63 93 61 72 NIL
10 64 90 60 70 NIL 61 89 58 68 NIL 62 96 55 69 NIL 65 106 65 79 NIL
11 66 90 59 69 0.4 67 91 58 69 0.4 69 86 56 66 0.2 65 95 60 72 NIL 67 92 62 72 NIL 63 92 64 73 NIL
12 57 95 59 71 NIL 58 96 61 73 NIL 61 96 64 75 NIL
13 54 90 59 69 0.2 57 90 61 71 NIL 55 88 61 70 NIL 59 89 62 71 NIL 65 115 84 94 NIL
14 60 91 58 69 NIL 62 96 63 74 NIL 68 126 83 97 NIL
15 68 124 88 100 NIL
16 60 89 61 70 NIL 59 90 62 71 NIL 60 90 63 72 NIL 62 112 76 88 NIL
17 62 90 61 71 NIL 64 117 75 89 NIL
18 59 89 61 70 0.2 60 90 62 71 NIL 64 90 59 69 NIL 67 99 65 76 NIL 68 121 67 85 NIL
19 58 92 61 71 NIL 65 96 68 77 NIL 68 106 66 79 NIL
20 58 89 60 70 0.6 56 82 50 61 0.2 54 84 52 63 0.2 58 84 52 63 NIL 67 104 63 77 NIL 69 108 76 87 NIL
21 56 88 56 67 0.2 59 89 58 68 0.2 60 90 57 68 0.2 62 89 57 68 0.2 60 88 59 69 NIL 63 90 64 73 NIL
22
23
24 56 89 57 68 0.2 53 86 59 68 0.2 57 87 58 68 NIL 57 87 62 70 NIL 56 90 64 73 NIL 60 92 61 71 NIL
25 62 85 58 67 0.2 60 84 56 65 0.2 59 88 59 69 NIL 63 95 61 72 NIL 65 98 61 73 NIL
SL.NO 85 MIN 90 MIN 95 MIN70 MIN 75 MIN 80 MIN
HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO % HR SBP DBP MAP ISO %
1 74 96 58 71 NIL 76 94 64 74 NIL 70 96 66 76 NIL
2
3
4 78 90 60 70 1.8 73 90 58 69 1.8 71 89 57 68 NIL 73 91 62 72 NIL 87 97 62 74 NIL
5 66 86 58 67 1.6 65 90 58 69 1.6 65 87 57 67 1.4 68 89 57 68 1.4 65 84 56 65 1.2 69 86 58 67 NIL
6 75 132 92 105 NIL 75 123 78 93 NIL 78 116 77 90 NIL
7
8 73 121 69 86 NIL 85 119 80 93 NIL
9 55 88 57 67 1.2 53 89 57 68 1.2 56 87 57 67 1 54 86 57 67 1 51 87 58 68 NIL 66 113 79 90 NIL
10 78 91 62 72 NIL
11 66 82 60 67 1.8 65 85 61 69 1.8 64 86 62 70 1.8 60 88 60 69 1.8 54 96 71 79 NIL 54 102 73 83 NIL
12
13 76 88 57 67 1.8 76 89 59 69 1.8 78 88 56 67 NIL 76 88 60 69 NIL 76 90 60 70 NIL 68 97 65 76 NIL
14
15 87 90 59 69 2 87 90 57 68 2 89 93 60 71 2 91 87 54 65 2 92 86 53 64 1.8 89 87 54 65 1.8
16
17 58 90 57 68 1.4 50 90 58 69 1.4 78 90 60 70 1.6 82 89 61 70 1.6 79 90 58 69 1.4 81 89 58 68 NIL
18 61 95 59 71 1 68 96 58 71 1.2 65 94 58 70 1.2 67 92 58 69 1.2 63 91 56 68 1.2 63 88 55 66 1
19
20 79 133 84 100 NIL
21 71 95 62 73 NIL 72 91 60 70 NIL 75 98 66 77 NIL 78 100 60 73 NIL
22
23 85 122 89 100 NIL
24
25 78 128 94 105 NIL
SL.NO 100 MIN 105 MIN 110 MIN 115 MIN 120 MIN 125 MIN
HYPER TENSION HYPO TENSION ARRYTHMIAS ISCHEMIA TACHYCARDIA BRADYCARDIA DURATION OF SURGERY
1 N N N N N N 79
2 N N N N N N 65
3 N N N N N N 82
4 N N N N N N 60
5 N N N N N Y 75
6 N N N N N Y 50
7 N N N N N N 85
8 N N N N N N 102
9 N N N N N N 95
10 N N N N N N 78
11 N N N N N N 90
12 N N N N N N 75
13 N N N N N N 82
14 N N N N N N 76
15 N N N N N N 67
16 N N N N N N 80
17 N N N N N N 70
18 N N N N N N 85
19 N N N N N N 72
20 N N N N N N 85
21 N N N N N N 96
22 N N N N N N 45
23 N N N N N N 55
24 N N N N N N 92
25 N N N N N N 80
SL.NO INTRAOP EVENTS
FROMME BOEZART SCALE AWAKENING TIME 15 30 45 60
1 1 5 2 2 2 2
2 1 6 3 2 2 2
3 1 4 2 2 2 2
4 2 6 3 2 2 2
5 2 3 2 2 2 2
6 2 8 3 3 2 2
7 2 10 3 3 2 2
8 1 5 2 2 2 2
9 1 6 3 2 2 2
10 2 4 2 2 2 2
11 1 5 2 2 2 2
12 2 4 2 2 2 2
13 1 4 2 2 2 2
14 2 5 2 2 2 2
15 2 3 2 2 2 2
16 1 4 2 2 2 2
17 1 6 3 3 2 2
18 1 6 3 2 2 2
19 2 5 2 2 2 2
20 1 8 3 3 2 2
21 1 3 2 2 2 2
22 1 4 2 2 2 2
23 2 4 3 3 2 2
24 2 4 2 2 2 2
25 1 6 3 3 2 2
RAMSAY SEDATION SCALESL.NO
Abstract 
Study objective: The aim of this study was to evaluate the effect 
dexmedetomidine infusion on the requirement of Isoflurane to produce 
controlled hypotension (mean arterial pressure of 60-70mmHg), quality of 
bloodless surgical field, duration of surgery and the awakening time in 
patients undergoing Functional Endoscopic Sinus Surgery (FESS). 
Design: Prospective randomized placebo-controlled study. 
Methods: 50 ASA I Patients age 18-60 years   diagnosed   having chronic 
sinusitis scheduled for FESS under general anesthesia were divided into two 
groups. Group D: Received 10-15 min prior to induction of anesthesia 1 µg/ 
kg iv bolus Dexmedetomidine followed by an infusion of 0.5 µg/ kg/ hr. 
Group C: Received 10-15 min before induction of anesthesia a normal saline 
rate similar to group D. Following a uniform premedication all patients were 
induced with inj .propofol and relaxed with inj. vecuronium bromide. After 
successful tracheal intubation, anesthesia was maintained with 66% nitrous 
oxide + 33% oxygen + isoflurane titrated to achieve a mean arterial pressure 
[MAP] of 60-70mmHg. Isoflurane and dexmedetomidine/saline infusion 
was stopped 10-15 minute prior to end of surgery. The residual 
neuromuscular blockade was reversed with neostigmine and glycopyrrolate. 
If at any stage heart rate was found to be less than 50 beats/ min, 0.3 mg 
atropine was administered every 2 –3 min till it reached above 60 beats/ min. 
Concentration of isoflurane was recorded in percentage every 5 min in the 
intraoperative period. This was averaged for analysis. Intraoperative surgical 
field was assessed by using 6 point Fromme-Boezaart scale. Awakening 
time in min [clearly telling his/her name] from the end of tracheal extubation 
was also recorded. Student “t” test was used to analyze the data statistically. 
P<0.05 was considered significant.  
Results:  A statistically significant (p-<0.001) reduction in intraoperative 
isoflurane requirement   in patients receiving dexmedetomitine infusion 
(0.387±0.102) in comparison to those receiving placebo (1.7±0.211). Both 
the group provided better visualization of the surgical field. The duration of 
surgery was statistically (p_ .004) low in Group D (76.84±14.174) compared 
to group C (94.1±25.083). The awakening time in min was statistically (p-
0.001) low in group D (5.12±1.691) compared to group C(9.72±1.100).  
Conclusion: Dexmedetomidine infusion helps in achieving a targeted 
reduction in MAP reduced intraoperative Isoflurane requirement, better 
blood less field, and faster awakening in patients undergoing Functional 
Endoscopic Sinus surgery. 
Key words: 
Dexmedetomidine , FESS, controlled hypotension.  
